BOCA RATON, Fla., Nov. 25, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has entered into a multi-product ANDA agreement with Pii (Pharmaceutics International, Inc.) (Hunt Valley, Maryland) under which Breckenridge and Pii expect to develop and commercialize several new ANDA's. Under the terms of the agreement, Pii will develop, manufacture and supply the products, and Breckenridge will market and distribute the products under its own label. The drugs, comprised of four unique dosage forms, and have combined U.S. market sales in excess of $1.6B, in the 12-month period ending September 30, 2014. The multi-product agreement contemplates the submission of multiple ANDA's with Paragraph IV certifications.
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 60 products in a variety of dosage forms and therapeutic categories. To date through 2014, Breckenridge has filed 23 ANDA's with Paragraph IV patent challenges.
About Pharmaceutics International, Inc.:
Pii (Pharmaceutics International, Inc.) is a privately held drug delivery solutions company providing dosage form development and GMP Manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley Maryland USA with European development and manufacturing facilities in the UK, Pii offers preformulation testing, formulation development and clinical trial material and commercial manufacture of parenteral, solid, semi-solid and liquid dosage forms.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/breckenridge-pharmaceutical-signs-multi-product-generic-agreement-with-pharmaceutics-international-inc-300001282.html
SOURCE Breckenridge Pharmaceutical, Inc.